Harbor Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Harbor Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Hold	500	–	–	0.03%	166
2026 Q1	$262K	Buy	+500	New	+$239K	0.04%	169

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Harbor Advisors's MDGL Position: Q2 2026 in Review

Harbor Advisors held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 500 shares worth $268K. The position accounts for 0.03% of the portfolio, ranked #166.

Harbor Advisors first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Harbor Advisors held 500 shares of Madrigal Pharmaceuticals worth $268K as of Q2 2026.
Harbor Advisors left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
Madrigal Pharmaceuticals made up 0.03% of Harbor Advisors's portfolio in Q2 2026, its #166 holding.
Harbor Advisors first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Harbor Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.